13D BioFibR Inc. Raises $550,000 in Seed Round to Commercialize Proprietary
Platform in Advanced Materials Market
HALIFAX, Nova Scotia, October 19, 2020 – 3D BioFibR Inc., an advanced biofibre materials company,
announced today it has raised $550,000 to fund development and commercialization of its tissue
engineering/biomedical device products and to scale up manufacturing of its novel biofibre-based
platform. This investment comes from a consortium of private investors, including $150,000 fromConcrete Ventures and $100,000 from Innovacorp.

“Completing this seed round of investment provides us with a solid financial base from which we canaccelerate our growth,” said Kevin Sullivan, CEO of 3D BioFibR. “I am proud of the team we have built todate. With the addition of talented scientists and our R&D capacity, we are ramping up our ability toprovide real solutions that address the growing need for advanced bio-composite materials that canfundamentally improve the world in which we live.”“Nature has evolved some of the most exquisite and advanced materials ever described. The physical,
mechanical and chemical properties of these naturally occurring fibers could help solve many of theengineering challenges we face, but no one has been able to make these biofibers on an industrial scaleusing existing techniques such as electrospinning and wet spinning”, said Dr. John Frampton, Canada
Research Chair in Biomaterials at Dalhousie University and Chief Scientific Officer at 3D BioFibR. “Our3D BioFibR team has solved the problem of making high quality biofibers using a proprietary, scalable
process which is already at least 600X more efficient than current technologies. To date, the problem ofmanufacturing scale has limited the industrial applications of these bio-composite materials. With ourability to scale production, we expect to transform the bio-composite market!”“3D BioFibR has an experienced team with scientific, industry and business leadership,” said Dr. Lidija
Marušić, life sciences investment manager at Innovacorp. “We have been following the progress of Dr.
Frampton’s work for a few years now. With the recent technology advances his team has made,combined with their ability to attract seasoned executives to the opportunity, we are excited to helptake their innovation to the global market.”“The applications for these materials are quite astounding and very diverse, ranging from biomedical, togreen textiles to aerospace and defense,” continued Sullivan. “Our corporate vision is to become thepremier supplier of high quality biofibers at a scale and quality that cannot be matched, and in doing so
provide the market with products and solutions that will revolutionize the advanced biomaterials
space.”

2
About 3D BioFibR Inc.
3D BioFibR is a biomaterial manufacturing company that produces naturally sourced, high valuebiofibers such as spider silk, collagen, chitosan and others. Preliminary fibre performance data shows
the potential applications of these fibres in several global markets, including biomedical engineering,green textiles, defense, and aerospace engineering. Formed in July 2020, 3D BioFibR was founded on thepioneering research of Dr. John Frampton. 3D BioFibR is focused on novel and proprietary methods ofbiofiber production that have a quality and scale that is currently not achievable with current methods.
3D BioFibR scientists have demonstrated the ability to make collagen fibres, termed CollaFibR™, that arestronger than natural tendons, and spider silk that is tougher than steel and 2000% more flexible. 3D
BioFibR’s vision is to become the global leader in the manmade production of natures’ strongest,
lightest and toughest materials at a scale and cost that makes them a competitive solution to theengineering challenges of our day. For more information, visit www.3DBioFibR.com.

INVESTOR RELATIONS CONTACT
Kevin Sullivan, CEO
3D BioFibR Inc.
E: Info@3DBioFibR.com
W: www.3DBioFibR.com
This news release contains “forward-looking statements,” which reflect the current expectations of the Company’s management
for future growth, results of operations, performance and business prospects. Forward-looking statements involve significant
known and unknown risks, uncertainties and assumptions.